Effectivness of Topical Furesemaide chronic on rhinosinusitis surgery
Phase 1
Recruiting
- Conditions
- chronic rhino sinusitis.js32.9Js32.9
- Registration Number
- IRCT20151123025202N3
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Patients with chronic rhinosinusitis with or without polyposis (primary or recurrent)
Ages between 18 and 60 years
Normalization of PT, PTT, INR, BT, CT and platelet count
Exclusion Criteria
have Bleeding disorders such as uncontrolled hemophilia
Uncontrolled history of thromboembolic events Uncontrolled
Receive heparin at 48 hours before surgery
ake aspirin within 3 days before surgery
Allergies to Furesemaide
Liver Cirrhosis
Systemic diseases such as hypertension, diabetes, heart failure
Patients with sinonasal tumor
side effects of Furesemaide
acute or chronic renal failure
Cardiac stent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduce bleeding in surgery site. Timepoint: end of surgery time. Method of measurement: The amount of blood collected in the suction bottle (after deduction of normal saline volume) and the weight of blood-stained packs.
- Secondary Outcome Measures
Name Time Method Quality of vision of the surgical field. Timepoint: during the surgery. Method of measurement: with Boezaart Grading questionair.